Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly ...
Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly ...
For more than a decade now, the global landscape of immuno-oncology (IO) clinical trials has been dominated by studies testing PD1 and PDL1 inhibitors, whether as monotherapy or in combinations.
SAN DIEGO – Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results